|
US6936439B2
(en)
|
1995-11-22 |
2005-08-30 |
Amgen Inc. |
OB fusion protein compositions and methods
|
|
US20030040467A1
(en)
|
1998-06-15 |
2003-02-27 |
Mary Ann Pelleymounter |
Ig/ob fusions and uses thereof.
|
|
CA2236163A1
(en)
*
|
1995-11-22 |
1997-05-29 |
Amgen Inc. |
Methods of increasing lean tissue mass using ob protein compositions
|
|
ES2221717T3
(es)
|
1997-12-08 |
2005-01-01 |
Emd Lexigen Research Center Corp. |
Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
|
|
US7488590B2
(en)
|
1998-10-23 |
2009-02-10 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
ATE348163T1
(de)
|
1998-10-23 |
2007-01-15 |
Amgen Inc |
Thrombopoietin substitute
|
|
US6660843B1
(en)
*
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
AU1134000A
(en)
*
|
1998-10-27 |
2000-05-15 |
Eli Lilly And Company |
Prevention of muscle mass loss with leptin receptor ligands
|
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
WO2001010912A1
(en)
|
1999-08-09 |
2001-02-15 |
Lexigen Pharmaceuticals Corp. |
Multiple cytokine-antibody complexes
|
|
CA2391080A1
(en)
|
1999-11-12 |
2001-05-25 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Erythropoietin forms with improved properties
|
|
JP5179689B2
(ja)
|
2000-02-11 |
2013-04-10 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗体ベース融合タンパク質の循環系内半減期の増強
|
|
US20020090646A1
(en)
*
|
2000-05-03 |
2002-07-11 |
Amgen Inc. |
Calcitonin-related molecules
|
|
EP1278778A2
(en)
*
|
2000-05-03 |
2003-01-29 |
Amgen Inc., |
Modified peptides, comprising an fc domain, as therapeutic agents
|
|
CZ2003214A3
(cs)
|
2000-06-29 |
2003-08-13 |
Merck Patent Gmbh |
Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu
|
|
WO2002057435A2
(en)
*
|
2001-01-18 |
2002-07-25 |
Merck Patent Gmbh |
Bifunctional fusion proteins with glucocerebrosidase activity
|
|
DK1366067T3
(da)
|
2001-03-07 |
2012-10-22 |
Merck Patent Gmbh |
Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
|
|
US6992174B2
(en)
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
|
BR0209177A
(pt)
|
2001-05-03 |
2004-10-05 |
Merck Patent Gmbh |
Anticorpo especìfico a tumor recombinante e uso do mesmo
|
|
EP1454138B1
(en)
|
2001-12-04 |
2012-01-18 |
Merck Patent GmbH |
Immunocytokines with modulated selectivity
|
|
MXPA04011470A
(es)
|
2002-05-21 |
2005-02-14 |
Amgen Inc |
Compuestos heterociclicos sustituidos y metodos de uso.
|
|
ATE471946T1
(de)
|
2002-12-17 |
2010-07-15 |
Merck Patent Gmbh |
Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
|
|
KR101163424B1
(ko)
|
2003-12-30 |
2012-07-13 |
메르크 파텐트 게엠베하 |
Il-7 융합 단백질
|
|
EP1699821B1
(en)
|
2003-12-31 |
2012-06-20 |
Merck Patent GmbH |
Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
|
|
CA2552590A1
(en)
|
2004-01-05 |
2005-07-21 |
Emd Lexigen Research Center Corp. |
Interleukin-12 targeted to oncofoetal fibronectin
|
|
CA2580796C
(en)
|
2004-09-24 |
2013-03-26 |
Amgen Inc. |
Modified fc molecules having peptides inserted in internal loop regions
|
|
CN101072793B
(zh)
|
2004-12-09 |
2012-06-20 |
默克专利有限公司 |
具有降低的免疫原性的il-7变体
|
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
|
US8227408B2
(en)
|
2005-09-07 |
2012-07-24 |
Neurotez, Inc. |
Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
|
|
TW201920257A
(zh)
|
2008-04-11 |
2019-06-01 |
日商中外製藥股份有限公司 |
重複結合複數個抗原的抗原結合分子
|
|
KR20110028457A
(ko)
|
2008-05-21 |
2011-03-18 |
뉴로테즈 인코포레이티드 |
신경섬유 매듭과 연관된 신경변성 장애를 치료하는 방법
|
|
WO2009149379A2
(en)
|
2008-06-05 |
2009-12-10 |
Regents Of The University Of Michigan |
Use of leptin for the treatment of fatty liver diseases and conditions
|
|
CA2742600A1
(en)
|
2008-11-04 |
2010-05-14 |
Nikolaos Tezapsidis |
Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
|
|
AU2010238858A1
(en)
|
2009-04-22 |
2011-12-08 |
Merck Patent Gmbh |
Antibody fusion proteins with modified FcRn binding sites
|
|
TWI654203B
(zh)
|
2010-11-30 |
2019-03-21 |
Chugai Seiyaku Kabushiki Kaisha |
具有鈣依存性的抗原結合能力之抗體
|
|
SG10201609665PA
(en)
|
2011-02-25 |
2017-01-27 |
Chugai Pharmaceutical Co Ltd |
FcɣRIIb-SPECIFIC Fc ANTIBODY
|
|
JP6322411B2
(ja)
|
2011-09-30 |
2018-05-09 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
|
CN111529535A
(zh)
|
2012-09-27 |
2020-08-14 |
儿童医学中心公司 |
用于治疗肥胖症的化合物和其使用方法
|
|
PT3074033T
(pt)
|
2013-11-26 |
2019-02-08 |
Childrens Medical Ct Corp |
Compostos para o tratamento de obesidade e métodos de utilização dos mesmos
|
|
US20170209408A1
(en)
|
2014-04-03 |
2017-07-27 |
The Children's Medical Center Corporation |
Hsp90 inhibitors for the treatment of obesity and methods of use thereof
|
|
MX2017005774A
(es)
|
2014-12-19 |
2017-07-28 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
|
|
EA201791366A1
(ru)
|
2014-12-19 |
2018-02-28 |
Чугаи Сейяку Кабусики Кайся |
Антитела к c5 и способы их применения
|
|
CN114773469B
(zh)
|
2015-02-05 |
2025-12-19 |
中外制药株式会社 |
包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il-8-结合抗体及其应用
|
|
EP3394098A4
(en)
|
2015-12-25 |
2019-11-13 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE
|
|
CN116271014A
(zh)
|
2016-08-05 |
2023-06-23 |
中外制药株式会社 |
用于预防或治疗il-8相关疾病的组合物
|
|
DK3509624T3
(da)
|
2016-09-12 |
2023-11-13 |
Amryt Pharmaceuticals Inc |
Fremgangsmåder til detektering af anti-leptin-neutraliserende antistoffer
|
|
WO2018139623A1
(en)
|
2017-01-30 |
2018-08-02 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-sclerostin antibodies and methods of use
|